Skip to content

Interest Paid at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$1.75M+600%
Roivant Sciences logo
Roivant SciencesROIV
$0-100%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$62.14M-21.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$6.08M-33.5%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$65K-15.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.4M-20.9%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestPaidNet.

The official record: IDEAYA Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s interest paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s interest paid?
IDEAYA Biosciences, Inc. (IDYA) reported interest paid of $0 in Q4 2025.
What is the long-term trend for IDEAYA Biosciences, Inc.'s interest paid?
Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s interest paid has grown at a -100.0% compound annual growth rate (CAGR), from $71K to $0.
What does interest paid mean?
Supplemental disclosure of total cash interest paid on all debt and lease obligations during the period.